<DOC>
	<DOCNO>NCT02095054</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose combination regorafenib cetuximab give patient advance solid tumor . The safety effectiveness drug combination also study .</brief_summary>
	<brief_title>Regorafenib Cetuximab Patients With Advanced Malignancy</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign dose level study drug base join study . Up 5 dose level combination regorafenib cetuximab test . Up 3 participant enrol dose level . The first group participant receive low dose level combination . Each new group receive high dose either regorafenib cetuximab group , intolerable side effect see . This continue high tolerable dose combination regorafenib cetuximab find . Once high tolerable dose combination find , 10 participant may enrol . This group ( call Dose Expansion group ) enrol help researcher study safety effectiveness dose level combination . Study Drug Administration : Each study cycle 28 day . You take regorafenib mouth Days 1-5 , 8-12 , 15-19 cycle . You swallow whole capsule 1 cup water ( 8 ounce ) 1 time day . Do break , chew , open capsule . The doctor discus . You receive cetuximab vein 1-2 hour Days 1 , 8 , 15 , 22 cycle . Study Visits : At cycle , ask complete questionnaire study team well understand symptom may relate use study drug . On Day 1 Cycle 1 , blood ( 4 teaspoon ) urine collect routine test pharmacodynamic ( PD ) test . PD test measure level study drug body may affect disease . Between Days 8 14 , Days 15 21 , Days 22 28 Cycle 1 : - Blood ( 4 teaspoon ) draw routine test . On Day 1 Cycles 2 beyond : - You physical exam . - Urine collect routine test . Once week , blood ( 4 teaspoon ) draw routine test . Every cycle ( every 8 week ) : - You x-ray CT scan check status disease . Length Study : You may continue receive regorafenib cetuximab long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . You study end-of-study visit . End Study Visit : About 30 day last dose study drug : - You physical exam . - Blood ( 4 teaspoon ) urine collect routine PD test test . - You x-ray CT scan check status disease . Follow-up : You ask health problem may side effect . If study doctor think need , may follow-up long period time . This investigational study . Regorafenib FDA approve treatment metastatic colorectal cancer . Cetuximab FDA approve treatment K-Ras wild type colorectal cancer well head neck cancer . The combination regorafenib cetuximab currently use advance solid tumor patient research purpose . Up 83 patient enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Patient must &gt; = 18 year age . 2 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy induces CR rate least 10 % improve survival least three month . 3 . Patients must evaluable measurable disease RECIST criterion solid tumor . 4 . Ability understand willingness sign write informed consent document . 5 . Patients must &gt; /= 4 week beyond treatment chemotherapy radiotherapy , must recover &lt; /= grade 2 toxicity treatmentlimiting toxicity prior therapy . ( Exception : patient may receive palliative low dose radiotherapy limbs 14 week therapy provide pelvis , rib , sternum , scapula , vertebra skull include radiotherapy field ) . Also , patient receive nonchemotherapeutic biologic agent need wait least five halflives four week , whichever short , last day treatment . Exception : No washout cetuximab regorafenib required patient receive prior cetuximab regorafenib recover treatmentrelated toxicity Grade &lt; /= 1 . 6 . ECOG performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) . 7 . Patients must : leukocyte &gt; /= 3,000/mL ; absolute neutrophil count &gt; /= 1,000/mL ; platelet &gt; /=75,000/mL ; creatinine &lt; /= 2 X ULN ; total bilirubin &lt; /= 2.0 ; ALT ( SGPT ) &lt; /= 3 X ULN ; Exception patient liver metastasis : total bilirubin &lt; /= 3 x ULN ; AST ( SGOT ) ALT ( SGPT ) &lt; /= 5 X ULN . 8 . Patients become pregnant breastfeed study . Sexually active patient must agree use contraception prior study entry , duration study participation , 30 day last dose . 1 . KRAS mutate colorectal cancer . 2 . Major surgery within 28 day prior first dose study medication . 3 . Pregnant lactating woman . 4 . Patients hemoptysis within 28 day prior enter study . 5 . Patients clinically significant unexplained bleeding within 28 day prior enter study . 6 . Uncontrolled systemic vascular hypertension ( Systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg medication ) . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic Day 1 . 8 . Patients clinically significant cardiovascular disease : 1 ) . History CVA within 6 month ; 2 ) . Myocardial infarction unstable angina within 6 month ; 3 ) . Unstable angina pectoris ; 4 ) . New York Heart Association Class III great congestive heart failure . 9 . Patients untreated progress brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>Advanced malignancy</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Regorafenib</keyword>
	<keyword>Stivarga</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>C225</keyword>
	<keyword>Erbitux</keyword>
	<keyword>IMC-C225</keyword>
	<keyword>MOAB C225</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Survey</keyword>
</DOC>